Press Releases

Cell Signaling Technology (CST) press releases are grouped by year and linked below.

2012

• Ventana to collaborate with Pfizer and Cell Signaling Technology, Inc. on companion diagnostic to identify lung cancer patients with ALK gene rearrangements | January 9

2011

• Cell Signaling Technology, Inc. wins Life Science Industry Awards in “Best Performing Antibodies” and “Best Breakthrough Products Cancer Research” Categories | December 5
• Cell Signaling Technology, Inc. Grants a Patent License to Pfizer | July 5
• Cell Signaling Technology, Inc. Announces License in Personalized Cancer Diagnostics | March 14
• Cell Signaling Technology, Inc. Announces Joint Commercialization Partnership with Astellas Pharma in Cancer Personalized Medicine | February 23

2009

• Cell Signaling Technology, Inc. Acquires BIOKÉ, B.V. and Expands Operations to Europe | July 10

2008

• Cell Signaling Technology, Inc. Announces Renewal of PhosphoScan^® Proteomics Research Project for Lead Compound Biomarker Discovery | Nov 6
• Cell Signaling Technology, Inc. Donation to Beverly High | June 18
• Cell Signaling Technology, Inc. Expands Operations Overseas | April 8
• CST Announces Continued Collaboration with AstraZeneca to Provide CST’s PhosphoScan^® Platform for Kinase Inhibitor Proteomic Profiling | February 12
• CST Announces Continued PhosphoScan^® Proteomics Research Project with Bristol-Myers Squibb for Kinase Inhibitor Profiling | February 5
• CST and TTP LabTech Collaborate to Develop and Co-Market Antibodies and Acumen^® Cytometric Assay Solutions for High Content Screening and Drug Discovery | January 31

2007

• CST Goes Green. | November 8
• CST Announces PhosphoScan^® Profiling Technology & PhosphoSite^® Knowledgebase | October 31
• CST Expands its PhosphoScan^® Patent Portfolio | March 27
• CST Announces Alliance with Merck to Provide PhosphoScan^® Proteomics & Antibody Development | March 27

2006

• CST Announces Alliance with AstraZeneca to Provide Rabbit Monoclonal Technologies | December 20
• CST Announces a Research Project with Bristol-Myers Squibb Company | December 5
• CST Demonstrates the Discovery Capabilities of its PhosphoScan^® Proteomics Platform | August 3
• CST Expands Partnership with Bio-Rad to Develop Phosphoprotein Assays | June 6
• CST Continues Collaboration with AstraZeneca to Provide CST's PhosphoScan^® Platform | April 12
• CST Announces Expansion of Studies with AstraZeneca to Evaluate CST's PhosphoScan^® Platform | January 9

2005

• CST Announces Pilot Study to Evaluate CST's PhosphoScan^® Platform | August 1
• CST Announces Pilot Study for Chiron Corporation | May 31

2004

• CST Announces Pilot Study for Aventis | September 20
• CST Announces Partnership with AstraZeneca to Identify Biomarkers | June 12
• CST and LI-COR Biosciences, Inc. Joint Marketing Agreement | June 1
• CST and Zeptosens AG Antibody Agreement | April 19
• CST and ProQinase GmbH Drug Discovery Partnership | March 22

2003

• CST Launches PhosphoSite^® Database | November 17
• CST Launches SignalSilence^® siRNA Kits | November 17
• ACLARA and CST Antibody Agreement | November 17
• Dana-Farber, Phosphoproteomics, and CST Phospho-Peptide Agreement | October 23
• Bio-Rad and CST Research, Supply and Co-Marketing Agreement | August 26
• CST and Beckman Coulter, Inc. Co-Development Co-Marketing Agreement | February 20

2002

• CST Patents Novel “Motif Antibody” Technology | October 22
• CST and Alliance for Cellular Signaling Collaboration | January 9